Inhalable Food-Grade MOFs Loaded Gas Messenger for Acute Lung Injury Treatment by Pulmonary Delivery

Acute lung injury (ALI) is a serious clinical disease the severe stage of which develops into acute respiratory distress syndrome (ARDS), with a high mortality rate of 35 to 40%. Despite decades of research and development of drugs such as corticosteroids and β-2 adrenergic agonists, treatment efficacy has been limited due to an insufficient drug concentration reaching the lungs. Here, a food-grade γ-cyclodextrin-based metal-organic framework (γCD-MOF) modified with cholesterol (CHS) is developed to load sulfur dioxide (SO<sub>2</sub>) as a dry powder inhaler (DPI) platform (CHS-CD-MOF@SO<sub>2</sub>) for ALI treatment. CHS-CD-MOF@SO<sub>2</sub> has suitable storage stability and excellent aerodynamic characteristics, with a fine particle fraction (FPF) of 40%, a geometric standard deviation (GSD) value of 1.61, and a mass median aerodynamic diameter (MMAD) of 4.8 μm, which can effectively target the lungs. By employing rhodamine B (RhB) as a fluorescence indicator, in vivo fluorescence imaging confirms the superior lung-targeting capability of CHS-CD-MOFs. CHS-CD-MOF@SO<sub>2</sub> can release 92.3 ± 4.4% of SO<sub>2</sub> in PBS solution within 5 min. What's more, the permeability of simulated lung fluid within 30 min is as high as 85%, which has the potential for rapid treatment of ALI. In an ALI mouse model, CHS-CD-MOF@SO<sub>2</sub> reduces the expression of pro-inflammatory factors tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6 by regulating the P38 and nuclear factor kappa B (NF-κB) pathways. It also significantly improves the lung tissue dry/wet ratio and reduces neutrophil infiltration. Importantly, this treatment achieves therapeutic outcomes in key efficacy parameters that was comparable to or better than those of dexamethasone (DXMS), a frontline drug for ALI, underscoring its significant therapeutic potential. This study presents a novel strategy for treating ALI using a DPI-based gas messenger platform. This study provides a novel therapeutic strategy to treat ALI using DPI-loaded gas messengers.

Authors

Institutions

Publication Details

Journal
ACS Applied Materials & Interfaces
Published
2025-12-11
DOI
https://doi.org/10.1021/acsami.5c20962
Primary Topic
Inhalation and Respiratory Drug Delivery
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Inhalable Food-Grade MOFs Loaded Gas Messenger for Acute Lung Injury Treatment by Pulmonary Delivery

Fu‐Zhong Zhang, Minfeng Zeng, Bang‐Jing Li, Junfeng Feng et al.
ACS Applied Materials & Interfaces
Inhalation and Respiratory Drug Delivery
article

Inhalable Food-Grade MOFs Loaded Gas Messenger for Acute Lung Injury Treatment by Pulmonary Delivery

Fu‐Zhong Zhang, Minfeng Zeng, Bang‐Jing Li, Junfeng Feng, Jing Li, Sheng Zhang, Ye-Tao Zhang, Yu-Ting Che, Zhixuan Hu
article en

Abstract

Acute lung injury (ALI) is a serious clinical disease the severe stage of which develops into acute respiratory distress syndrome (ARDS), with a high mortality rate of 35 to 40%. Despite decades of research and development of drugs such as corticosteroids and β-2 adrenergic agonists, treatment efficacy has been limited due to an insufficient drug concentration reaching the lungs. Here, a food-grade γ-cyclodextrin-based metal-organic framework (γCD-MOF) modified with cholesterol (CHS) is developed to load sulfur dioxide (SO<sub>2</sub>) as a dry powder inhaler (DPI) platform (CHS-CD-MOF@SO<sub>2</sub>) for ALI treatment. CHS-CD-MOF@SO<sub>2</sub> has suitable storage stability and excellent aerodynamic characteristics, with a fine particle fraction (FPF) of 40%, a geometric standard deviation (GSD) value of 1.61, and a mass median aerodynamic diameter (MMAD) of 4.8 μm, which can effectively target the lungs. By employing rhodamine B (RhB) as a fluorescence indicator, in vivo fluorescence imaging confirms the superior lung-targeting capability of CHS-CD-MOFs. CHS-CD-MOF@SO<sub>2</sub> can release 92.3 ± 4.4% of SO<sub>2</sub> in PBS solution within 5 min. What's more, the permeability of simulated lung fluid within 30 min is as high as 85%, which has the potential for rapid treatment of ALI. In an ALI mouse model, CHS-CD-MOF@SO<sub>2</sub> reduces the expression of pro-inflammatory factors tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and IL-6 by regulating the P38 and nuclear factor kappa B (NF-κB) pathways. It also significantly improves the lung tissue dry/wet ratio and reduces neutrophil infiltration. Importantly, this treatment achieves therapeutic outcomes in key efficacy parameters that was comparable to or better than those of dexamethasone (DXMS), a frontline drug for ALI, underscoring its significant therapeutic potential. This study presents a novel strategy for treating ALI using a DPI-based gas messenger platform. This study provides a novel therapeutic strategy to treat ALI using DPI-loaded gas messengers.

ACS Applied Materials & InterfacesVol. 17(51)
Zunyi Medical University (CN), Chinese Academy of Sciences (CN), Sichuan University (CN), Polymer Research Institute (RU), Stomatology Hospital (CN), Chengdu Institute of Biology (CN), University of Chinese Academy of Sciences (CN)
Openalex Percentile: Top 42%
Inhalation and Respiratory Drug Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.